Owen Wallace's Insider Trades & SAST Disclosures
Owen Wallace's most recent trade in Monte Rosa Therapeutics Inc was a trade of 119,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Jan. 2, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Owen Wallace.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Monte Rosa Therapeutics Inc | Owen Wallace | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 119,000 | 119,000 | - | - | Stock Option (Right to Buy) | |
| Monte Rosa Therapeutics Inc | Owen Wallace | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 135,000 | 135,000 | - | - | Stock Option (Right to Buy) | |
| Monte Rosa Therapeutics Inc | Owen Wallace | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 117,450 | 117,450 | - | - | Stock Option (Right to Buy) | |
| Monte Rosa Therapeutics Inc | Owen Wallace | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Apr 2021 | 387,069 | 387,069 | - | - | Stock Option (Right to Buy) | |
| Monte Rosa Therapeutics Inc | Owen Wallace | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Apr 2021 | 113,298 | 113,298 | - | - | Stock Option (Right to Buy) | |
| Fulcrum Therapeutics Inc | Owen Wallace | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Sep 2020 | 6,350 | 75,592 | - | - | Stock Option (right to buy) | |
| Fulcrum Therapeutics Inc | Owen Wallace | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.84 per share. | 14 Sep 2020 | 6,350 | 133,438 (0%) | 0% | 7.8 | 49,784 | Common Stock |
| Fulcrum Therapeutics Inc | Owen Wallace | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jul 2020 | 2,951 | 81,942 | - | - | Stock Option (right to buy) | |
| Fulcrum Therapeutics Inc | Owen Wallace | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 08 Jul 2020 | 2,951 | 127,088 (0%) | 0% | 20 | 59,020 | Common Stock |
| Fulcrum Therapeutics Inc | Owen Wallace | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.84 per share. | 08 Jul 2020 | 2,951 | 130,039 (0%) | 0% | 7.8 | 23,136 | Common Stock |
| Fulcrum Therapeutics Inc | Owen Wallace | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.84 per share. | 30 Jun 2020 | 141 | 127,229 (0%) | 0% | 7.8 | 1,105 | Common Stock |
| Fulcrum Therapeutics Inc | Owen Wallace | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2020 | 141 | 84,893 | - | - | Stock Option (right to buy) | |
| Fulcrum Therapeutics Inc | Owen Wallace | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 30 Jun 2020 | 141 | 127,088 (0%) | 0% | 20 | 2,820 | Common Stock |
| Fulcrum Therapeutics Inc | Owen Wallace | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.84 per share. | 28 May 2020 | 2,232 | 129,320 (0%) | 0% | 7.8 | 17,499 | Common Stock |
| Fulcrum Therapeutics Inc | Owen Wallace | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 28 May 2020 | 2,232 | 127,088 (0%) | 0% | 20 | 44,640 | Common Stock |
| Fulcrum Therapeutics Inc | Owen Wallace | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 May 2020 | 2,232 | 85,034 | - | - | Stock Option (right to buy) | |
| Fulcrum Therapeutics Inc | Owen Wallace | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.84 per share. | 27 May 2020 | 448 | 127,536 (0%) | 0% | 7.8 | 3,512 | Common Stock |
| Fulcrum Therapeutics Inc | Owen Wallace | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 May 2020 | 448 | 87,266 | - | - | Stock Option (right to buy) | |
| Fulcrum Therapeutics Inc | Owen Wallace | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 27 May 2020 | 448 | 127,088 (0%) | 0% | 20 | 8,960 | Common Stock |
| Fulcrum Therapeutics Inc | Owen Wallace | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 26 May 2020 | 412 | 127,088 (0%) | 0% | 20 | 8,240 | Common Stock |
| Fulcrum Therapeutics Inc | Owen Wallace | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 May 2020 | 412 | 87,714 | - | - | Stock Option (right to buy) | |
| Fulcrum Therapeutics Inc | Owen Wallace | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.84 per share. | 26 May 2020 | 412 | 127,500 (0%) | 0% | 7.8 | 3,230 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges